Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoDSKYF -9.17%79 Equity-to-Asset is 0.41 as of Jun. 2026, which is 33% below its 10-year median of 0.61. GuruFocus rates DSKYF with a GF Score™ of 79/100 and a GF Value™ of $31.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Daiichinkyo Co ranks worse than 73.91% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Daiichinkyo Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $10,591 Mil. Daiichinkyo Co's Total Assets for the quarter that ended in Jun. 2026 was $25,593 Mil.
Therefore, Daiichinkyo Co's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.41.
The historical rank and industry rank for Daiichinkyo Co's Equity-to-Asset or its related term are showing as below:
DSKYF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41 Med: 0.61 Max: 0.65
Current: 0.41
During the past 13 years, the highest Equity to Asset Ratio of Daiichinkyo Co was 0.65. The lowest was 0.41. And the median was 0.61.
DSKYF's Equity-to-Asset is ranked worse than 73.91% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs DSKYF: 0.41
Daiichinkyo Co (OTCPK:DSKYF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Daiichinkyo Co Equity-to-Asset Related Terms
Daiichinkyo Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DSKYF vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Daiichinkyo Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (DSKYF) has a Equity-to-Asset of 0.41 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Daiichinkyo Co and its competitors. This is 33% below median its historical median of 0.61. Over the past decade, Daiichinkyo Co's Equity-to-Asset has ranged from 0.41 to 0.65. According to the industry distribution chart, Daiichinkyo Co ranks #745 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 73.9%.
Is Daiichinkyo Co's Equity-to-Asset too high?
Daiichinkyo Co's current Equity-to-Asset of 0.41 is 33% below median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 0.65. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Daiichinkyo Co's value of 0.41 is 31.7% below this industry median. Based on the distribution chart, Daiichinkyo Co ranks #745 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #745 out of 1008 companies for Equity-to-Asset. This places Daiichinkyo Co in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Daiichinkyo Co's value of 0.41 is 31.7% below this benchmark. Historically, Daiichinkyo Co's own Equity-to-Asset has ranged from 0.41 to 0.65 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 0.60, Daiichinkyo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current Equity-to-Asset of 0.41 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Equity-to-Asset is 0.41, which is 33% below median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $31.94, compared to a current price of $16.65 — trading 47.9% below its estimated fair value. The current Equity-to-Asset is 0.41, which is 33% below median its 10-year median of 0.61 and 31.7% below the Drug Manufacturers industry median of 0.60. Daiichinkyo Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current Equity-to-Asset is 0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $16.65 is trading 47.9% below its estimated GF Value™ of $31.94.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
Equity-to-Asset: 0.41 (33% below median its 10-year median of 0.61)
GF Value™: $31.94 vs. price of $16.65 (47.9% below fair value)
Industry Position: 31.7% below the Drug Manufacturers median (#745 of 1008)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
79GF Score
Get the complete analysis for DSKYF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
